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Background
Colorectal cancer is the second leading cause of cancer
death in the world. The cause of high mortality is that
almost half the cancers are detected at an advanced stage
of disease. In addition to surgical and chemotherapy
treatment in recent years, applied monoclonal antibody
therapy may target against growth factors, and particu-
larly against the receptors for growth factors. In clinical
practice, an antibody against vascular endotelial growth
factor (VEGF) - bevacizumab-is already used. VEGF is
the factor responsible for neoangiogenesis and it was
considered as a possible prognostic marker of disease
progression. The correlation of higher levels of VEGF
with the response to applied therapy, disease progress
levels and a poor prognosis in patients with solid tumors
is recently discussed. Transforming growth factor - beta
(Transforming growth factor - beta, TGF-beta) is also
neoangiogenetic and highly immunosuppressive factor.
TGF-beta suppresses natural immunity against tumors.
The TGF is considered as another possible prognostic
marker of disease progression.
The purpose of the study was to monitor immune
responses in patients with colorectal cancer, particularly
the examination of cellular as well as humoral immunity.
TGF beta, and VEGF production was monitored.
Methods
19 patients included in the research project were imple-
mented routine cancer teratment, including bevacizumab.
Basic parameters (histological type and grade, proliferative
marker) were established. Patients were evaluated by a
cancer clinical immunologist to exclude immune disor-
ders, allergic or autoimmune origin. TGF-beta, VEGF
were mesured by ELISA and anti-tumor cellular immunity
(CD4, CD8, B cells) were measured by flow cytometry.
Results
In patients with colorectal cancer mainly depression in
cellular immunity was found. Immunglobulin plasma level
was dicreased as well (mainly IgG4 subtype). Most patients
have shown clinical symptoms of immunodeficiency (fre-
quent infections of respiratory tract, herpetic infections)
TGF beta as well as VEGF plasma level were increased.
Conclusion
Correlation of these factors and the state of anticancer
immunity could help in the future as a marker and contri-
bute to the selection of targeted immune therapy in
patients with colorectal cancer.
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